For the next 5.5 years, Prof Pierre-Emmanuel Rautou will coordinate 21 relevant European institutions to analyse and integrate data and biological samples from 2,000 patients, validate the results in animal models and test the most promising resultant therapy in a phase II clinical trial.
Research suggest that the characteristics of each individual are the culprit of the high mortality rates of cirrhotic patients. This heterogeneity compels to find personalized treatments, based on underlying biological mechanisms. The patients participating in the DECISION research will take advantage of these treatments, while future patients will benefit of the novel combinatorial therapies and improved guidelines derived from the project.